The goal of the present study was to demonstrate that intracoronary platelet deposition may trigger intense vasoconstriction of large epicardial coronary arteries in vivo and that this is largely mediated by thromboxane A2 and serotonin released by activated platelets. Cyclic flow variations (progressive declines in blood flow followed by sudden restorations of flow) due to recurrent intracoronary platelet activation and thrombus formation were induced by damaging the endothelium and placing a cylindrical constrictor on the left anterior descending coronary artery (LAD) in open-chest, anesthetized dogs. Coronary diameters were measured in vivo by means of ultrasonic crystals sutured on the LAD immediately distal to the constrictor (LADI) and 1 cm below (LAD2) and on the circumflex coronary artery (Cx). Coronary artery diastolic diameters were measured continuously before and during cyclic flow variations and after they were abolished by administration of LY53857, a serotonin-receptor antagonist (group 1, n =7), or SQ29548, a thromboxane-receptor antagonist (group 2, n = 7). During cyclic flow variations, at the nadir of coronary flow, LADI (a site of maximal platelet accumulation) cross-sectional area decreased by 52±10% and 38±6% in group 1 and 2 animals, respectively (p <0.001 compared with values recorded during a brief LAD occlusion obtained by a suture snare), whereas LAD2 (a site of minimal or no platelet accumulation) cross-sectional area did not differ from that recorded during the brief LAD occlusion. SQ29548 abolished cyclic flow variations in seven of seven dogs and LY53857 in six of seven, but they affected the increased coronary vasoconstriction differently: LADI cross-sectional area increased by 32±N6% of the control value in SQ29548-treated animals, whereas it returned to baseline dimension values in the LY53857-treated group as these interventions also abolished the cyclic flow variations. We conclude that a marked coronary vasoconstriction may be triggered by local platelet deposition and that thromboxane A2 and serotonin are mediators of this vasoconstriction. (Circulation 1989;79:154-166) It is currently believed that the pathophysiology of unstable angina is a primary reduction in coronary blood flow. 
The goal of the present study was to demonstrate that intracoronary platelet deposition may trigger intense vasoconstriction of large epicardial coronary arteries in vivo and that this is largely mediated by thromboxane A2 and serotonin released by activated platelets. Cyclic flow variations (progressive declines in blood flow followed by sudden restorations of flow) due to recurrent intracoronary platelet activation and thrombus formation were induced by damaging the endothelium and placing a cylindrical constrictor on the left anterior descending coronary artery (LAD) in open-chest, anesthetized dogs. Coronary diameters were measured in vivo by means of ultrasonic crystals sutured on the LAD immediately distal to the constrictor (LADI) and 1 cm below (LAD2) and on the circumflex coronary artery (Cx). Coronary artery diastolic diameters were measured continuously before and during cyclic flow variations and after they were abolished by administration of LY53857, a serotonin-receptor antagonist (group 1, n =7), or SQ29548, a thromboxane-receptor antagonist (group 2, n = 7). During cyclic flow variations, at the nadir of coronary flow, LADI (a site of maximal platelet accumulation) cross-sectional area decreased by 52±10% and 38±6% in group 1 and 2 animals, respectively (p <0.001
compared with values recorded during a brief LAD occlusion obtained by a suture snare), whereas LAD2 (a site of minimal or no platelet accumulation) cross-sectional area did not differ from that recorded during the brief LAD occlusion. SQ29548 abolished cyclic flow variations in seven of seven dogs and LY53857 in six of seven, but they affected the increased coronary vasoconstriction differently: LADI cross-sectional area increased by 32±N6% of the control value in SQ29548-treated animals, whereas it returned to baseline dimension values in the LY53857-treated group as these interventions also abolished the cyclic flow variations. We conclude that a marked coronary vasoconstriction may be triggered by local platelet deposition and that thromboxane A2 and serotonin are mediators of this vasoconstriction. (Circulation 1989; 79:154-166) It is currently believed that the pathophysiology of unstable angina is a primary reduction in coronary blood flow. [1] [2] [3] [4] [5] [6] In particular, there is a growing body of evidence indicating that in most patients, unstable angina is the consequence of sudden restorations of flow. These alterations in coronary blood flow have been referred to as cyclic flow variations and are caused by transient formation of platelet thrombi at the site of the coronary stenosis and endothelial injury.14-17Subsequent studies from our laboratory have demonstrated that serotonin (5HT) and thromboxane A2 (TXA2) released from activated platelets are two important mediators of cyclic flow variations in this canine model15,17"8 and that the tissue concentration of 5HT and TXA2 is markedly elevated in the coronary artery at the site of the stenosis. 18, 19 The primary goal of this investigation was to test the hypothesis that platelet activation and deposition with the consequent release of vasoactive substances, such as 5HT and TXA2 at sites of endothelial injury and coronary artery stenosis cause a marked vasoconstriction of the large epicardial coronary artery. A second goal of the present study was to demonstrate that 5HT and TXA2 are the mediators primarily responsible for this coronary vasoconstriction. Accordingly, measurements of the left anterior descending coronary artery diastolic diameter were obtained in vivo by means of an ultrasonic dimension gauge before and during intracoronary platelet activation and after administration of 5HT2 and TXA2-prostaglandin H2 receptor antagonists.
Materials and Methods Surgical Preparation
Nineteen mongrel dogs (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) branch of the LAD below the site of constriction, enabling the pressure gradient across the stenosis to be measured ( Figure 1 ).
Experimental Protocol
After all surgical procedures were completed, animals were allowed to stabilize for at least 30 minutes. Control hemodynamic measurements, including heart rate, systemic and coronary arterial pressure, and mean and phasic coronary blood flow velocity as well as external diameters of LAD1, LAD2, and Cx, were recorded continuously on a Hewlett-Packard (Model 7758) eight-channel recorder. A plastic cylindrical constrictor was placed around the LAD between the Doppler flow probe and the first pair of crystals ( Figure 1) minutes was started. After the diltiazem was discontinued, these animals received an intravenous bolus of SQ29548 to abolish cyclic flow variations as described above. Thirty minutes after abolition of cyclic flow variations, all of the animals were killed by an overdose of sodium pentobarbital, and the hearts were promptly excised. Thereafter, the LAD was dissected free from the surrounding tissue and divided into a segment proximal to the stenosis, a stenotic segment (portion of the LAD included in the plastic constrictor), and those two segments where the proximal (LADI) and the distal pair of crystals (LAD2) were sutured. Similarly, the portion of the Cx where the ultrasonic crystals were positioned as well as two other Cx segments that were not manipulated during the experiment were obtained. All arterial segments were rinsed rapidly in saline and subsequently fixed in 10% buffered formalin for later histologic assessment of endothelial damage and platelet deposition. For comparative purposes, histologic sections were obtained also from two dogs that received no treatment and that were killed at the nadir of coronary blood flow. Arterial segments isolated from dogs in whom radiolabeled platelets were injected were also placed in a gamma counter to measure`11in activity.
Measurement of Coronarv Diameter In Vivo
Coronary artery diameters were measured continuously with While external diameter was measured continuously, the internal radius and the cross-sectional areas of the vessels at the site of crystal implantation were calculated as previously described. 25, 26 Changes in LAD and Cx internal diameters and cross-sectional areas were related to values obtained before cyclic flow variations (control) but with the constrictor in place on the LAD. During cyclic flow variations, a marked decrease in distal LAD distending pressure occurs at the nadir of coronary blood flow ( Figure 2 ). To distinguish the passive decrease in LAD diameter consequent to a reduction of coronary distending pressure from actual vasoconstriction due to activation of arterial smooth muscle cells, we compared coronary artery dimensions obtained during cyclic flow variations with those recorded during a 10-second occlusion of the LAD produced by a suture snare placed proximally to the Doppler flow probe. The latter measurement was made early in the experiments before the onset of cyclic flow variations but with the constrictor in place.
Preparation of "'In-Labeled Platelets
In six SQ29548 -treated dogs, autologous platelets were isolated and labeled with "'In according to the method of Thakur et a132 before cyclic flow variations were established. After labeling, platelets were gently washed, resuspended in 5 ml autologous platelet poor plasma, and reinjected into the dog.32 Labeling efficiency defined as In bound to platelets "'In bound to platelets + unbound "'In activity was 80.5% (range, 61-90%). The viability of the platelets after radiolabeling was assessed in vivo by calculating the percentage of administered radioactivity bound to circulating platelets at different time intervals. Two, 4, 10, 30, and 60 minutes after the radiolabeled platelets were administered, a 1-ml blood sample was obtained from a peripheral vein. Platelets were isolated,32 and radioactivity was counted both in the platelets and in the platelet poor plasma. Only a small amount of radioactivity was found in platelet poor plasma (range, 3-7% Platelet Aggregation Studies Although LY53857 has been shown to possess no antagonist activity with respect to a variety of substances in vitro,21 no data are available regarding the interaction of LY53857 with TXA2 receptors. To exclude the possibility that LY53857 has important thromboxane receptor antagonistic properties, in vitro platelet aggregation was studied before and after the administration of LY53857 in three additional dogs at a dose of 0.1 mg/kg. Aggregation was induced in epinephrine-primed platelet rich plasma (10 ,uM) by a dose range (10, 25, 50 , and 100 mg) of U46619, a TXA2 mimetic.
Statistical Analysis
Values are expressed as mean ± SEM. Comparison between two means were made with Student's t test for group observations. One-way analysis of variance was used for multiple comparisons between groups. For comparisons of hemodynamics and coronary artery dimensions between groups, a two-way analysis of variance for a design with repeated measures was used. 
Hemodynamic Changes
Heart rates and aortic pressures did not change significantly during the study in both group 1 and 2 dogs (Table 1 ). More importantly, no changes in these two variables were observed after the administration of SQ29548 or LY53857. Distal coronary arterial pressures measured before the placement of the constrictors were consistently lower than aortic pressures in both groups. This difference can probably be attributed to the small size of the catheter used to cannulate the small side branch of the LADs. Table 2 summarizes the hemodynamic changes in the five dogs receiving nitroglycerin and diltiazem during cyclic flow variations.
Coronary Artery Dimension Changes
Representative waveforms for simultaneous coronary pressures, aortic pressures, phasic coronary blood velocity, niean coronary blood velocity, and coronary diameters (Cx, LADI, and LAD2) before, during, and after abolition of cyclic flow variations are shown in Figure 2 . The brief mechanical coronary artery occlusion caused a decrease in LADI cross-sectional area of 24 ± 7% and 14 ± 3% of the control values in group 1 and 2 dogs, respectively (p = NS). Likewise, LAD2 cross-sectional areas decreased by 18 ± 6% and 16 ± 3% as compared with control values in the same groups of animals. During cyclic flow variations at nadir flow, LAD1 cross-sectional area decreased by 52±10% and 38 ± 6% from control values in group 1 and 2 animals, respectively. These values were both significantly different from those obtained during the brief mechanical occlusion (Figure 3 In the present study, intracoronary platelet accumulation ratio after cyclic flow variations were abolished with SQ29548 averaged 57±9 in LAD segments immediately distal to the stenosis (LAD1), indicating that a marked platelet deposition occurred in those LAD arterial segments during cyclic flow alterations ( Figure 6 ). On the other hand, only trivial platelet accumulation was observed in the circumflex artery at the site of placement of the ultrasonic crystals and in the LAD2, where the second pair of crystals was sutured ( Figure 5 ), suggesting that important platelet deposition did not occur in those coronary arterial segments during cyclic flow variations as a result of vessel manipulation.
Microscopic analyses confirmed these findings: the highest histologic score for platelet deposition was associated with the highest`'In activity (Table 3) . Stenotic segments and segments just distal to those sites were characterized by loss of endothelium, degenerative changes in the media with focal infiltration by leucocytes (predominantly neutrophils) and mild-to-moderate deposition of platelets on the luminal surface without luminal obstruction ( Figure  7 ). Conversely, in the distal LAD (LAD2) and Cx segments, no or mild endothelial damage and no or very few platelets were evident by histologic analysis ( Figure 8 ). In the two dogs that did not receive pharmacologic intervention and were killed at the nadir of coronary blood flow, stenotic and immediately distal segments showed marked platelet and leucocyte accumulation and luminal obstruction ( Figure 9 ). Table 3 correlates the histologic findings with thè 111n-labeled platelet accumulation in six dogs receiving SQ29548.
Platelet Aggregation Studies
To determine whether LY53857 has also a TXA2
receptor antagonist activity, U46619-induced aggregation was allowed in epinephrine-primed canine platelets obtained before and after administration of LY53857 (n = 3) in vivo. Epinephrine was added to platelet rich plasma to prime platelets in all experiments because U46619 alone had a modest effect on aggregation (i.e., approximately 3%). Epinephrine (10 ,M) alone had no effect on aggregation. There was no difference in U46619-induced aggregation (measured as percentage of maximal transmission) before and after administration of LY53857 for concentrations of U46619 up to 100 mg. LAD1, left anterior descending coronary artery segments immediately distal to the stenosis, site of placement of the first pair of ultrasonic crystals; LAD2, left anterior descending coronary artery segments, 1-1.5 cm distal to the stenosis, site of placement of the second pair of ultrasonic crystals.
(See text for details.) Discussion In this experimental preparation, endothelial damage associated with coronary arterial constriction usually results in a cyclic pattern of reduction and restoration of flow that is caused by alternating platelet aggregation and subsequent dislodgement.14-18 It has been demonstrated that when platelets aggregate they releas4e several substances, including serotonin and TXA2, which are known to cause vasoconstriction and to further promote aggregation.35 38 Ashton et al,18 in the same animal preparation used in this study, have demonstrated that serotonin concentrations measured in the area of the LAD stenosis are 18-fold to 27-fold higher than those found in the LAD proximal to the stenosis and in the unmanipulated circumflex artery. Similarly, Schmitz et in activating and sustaining cyclic flow variations, also appear to be important mediators of the focal coronary vasoconstriction in vivo in this experimental model.
In the present study, both LY53857 and SQ29548 were shown to be very effective in abolishing cyclic flow variations. This is in agreement with preliminary results46,47 and a recent study from our laboratory23 in which we have shown that both LY53857, a specific and potent 5HT2 receptor antagonist, and SQ29548, a potent TXA2-prostaglandin H2 receptor antagonist, are effective in abolishing cyclic flow variations. However, they differently affected LAD dimensions: abolition of cyclic flow variations by SQ29548 administration was associated with a marked and prolonged dilatation of the LAD at both sites of placement of the ultrasonic crystals. The reason why S029548 dilated LAD1 and LAD2 is not clear, but it could be related to a relative predominance of an endogenous vasodilator after the blockade of TXA2 receptors. LY53857, in contrast, did not have any vasodilator effect on coronary vascular dimensions in stenosed LAD and normal circumflex arteries, but it did eliminate the increased vasoconstriction occurring at LADI during the cyclic flow variations.
It is currently believed that the primary mechanism responsible for the development of unstable angina is a reduction of myocardial oxygen supply rather than an increase in myocardial oxygen demand.1-'1 In particular, angiographic and angioscopic evidence suggest that plaque ulceration and coronary thrombosis are frequent findings in patients with unstable angina.7 In addition, metabolic studies have suggested that periodic platelet activation occurs in patients with unstable angina and that this may eventually lead to coronary occlusion by either formation of a thrombus or the release of platelet-derived vasoactive substances or both, which may in turn cause marked coronary vasoconstriction.7 In so far as data obtained in experimental preparations can be extrapolated to humans, the present observations suggest that intracoronary platelet deposition at a site of plaque ulceration may, indeed, cause vasoconstriction of a large epicardial coronary artery. Such vasoconstriction might be extremely pronounced in patients with unstable angina because atherosclerotic coronary arteries have been shown to be hypersensiby guest on April 30, 2017 http://circ.ahajournals.org/ Downloaded from tive to different vasoconstrictor substances.48 Additionally, from a therapeutic point of view, the administration of a TXA2-prostaglandin H2 receptor antagonist seems to possess the additional and very useful property of dilating the stenosed vessel. This effect could be potentially very desirable in the clinical setting.
In conclusion, our results demonstrate that activated platelets may cause increased coronary vasoconstriction in vivo at sites of coronary stenosis and endothelial injury as the result of their release of serotonin and TXA2.
